Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Invariant Natural Killer T Cell Agonist Modulates Experimental Focal and Segmental Glomerulosclerosis

Full text
Author(s):
Show less -
Pereira, Rafael L. [1] ; Reis, Vanessa O. [1] ; Semedo, Patricia [1] ; Buscariollo, Bruna N. [1] ; Donizetti-Oliveira, Cassiano [1] ; Cenedeze, Marcos A. [1] ; Soares, Maria Fernanda [1] ; Pacheco-Silva, Alvaro [2, 1] ; Savage, Paul B. [3] ; Camara, Niels O. S. [4, 1] ; Keller, Alexandre C. [5, 1]
Total Authors: 11
Affiliation:
[1] Univ Fed Sao Paulo, Dept Med Nefrol, Sao Paulo - Brazil
[2] Inst Israelita Ensino & Pesquisa Albert Einstein, Unidade Transplante Renal, Sao Paulo - Brazil
[3] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 - USA
[4] Univ Sao Paulo, Dept Imunol, Sao Paulo - Brazil
[5] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo - Brazil
Total Affiliations: 5
Document type: Journal article
Source: PLoS One; v. 7, n. 3 MAR 12 2012.
Web of Science Citations: 13
Abstract

A growing body of evidence demonstrates a correlation between Th2 cytokines and the development of focal and segmental glomerulosclerosis ( FSGS). Therefore, we hypothesized that GSL-1, a monoglycosylceramide from Sphingomonas ssp. with pro-Th1 activity on invariant Natural Killer T ( iNKT) lymphocytes, could counterbalance the Th2 profile and modulate glomerulosclerosis. Using an adriamycin( ADM)-based model of FSGS, we found that BALB/c mice presented albuminuria and glomerular degeneration in association with a Th2-like pro-fibrogenic profile; these mice also expressed a combination of inflammatory cytokines, such as IL-4, IL-1 alpha, IL-1 beta, IL-17, TNF-alpha, and chemokines, such as RANTES and eotaxin. In addition, we observed a decrease in the mRNA levels of GD3 synthase, the enzyme responsible for GD3 metabolism, a glycolipid associated with podocyte physiology. GSL-1 treatment inhibited ADM-induced renal dysfunction and preserved kidney architecture, a phenomenon associated with the induction of a Th1-like response, increased levels of GD3 synthase transcripts and inhibition of pro-fibrotic transcripts and inflammatory cytokines. TGF-beta analysis revealed increased levels of circulating protein and tissue transcripts in both ADM- and GSL-1-treated mice, suggesting that TGF-beta could be associated with both FSGS pathology and iNKT-mediated immunosuppression; therefore, we analyzed the kidney expression of phosphorylated SMAD2/3 and SMAD7 proteins, molecules associated with the deleterious and protective effects of TGF-beta, respectively. We found high levels of phosphoSMAD2/3 in ADM mice in contrast to the GSL-1 treated group in which SMAD7 expression increased. These data suggest that GSL-1 treatment modulates the downstream signaling of TGF-beta through a renoprotective pathway. Finally, GSL-1 treatment at day 4, a period when proteinuria was already established, was still able to improve renal function, preserve renal structure and inhibit fibrogenic transcripts. In conclusion, our work demonstrates that the iNKT agonist GSL-1 modulates the pathogenesis of ADM-induced glomerulosclerosis and may provide an alternative approach to disease management. (AU)

FAPESP's process: 07/07120-0 - The role of invariant natural killer T cells in the development of glomerulonephritis: mechanisms and perspectives
Grantee:Alexandre de Castro Keller
Support Opportunities: Research Grants - Young Investigators Grants